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The Reply  
Dr. Modarressi suggests in his letter that our interpretation of the TRUST study1 needs caution because patients who had a 
thyroid-stimulating hormone (TSH) level between 4.6 and 6.9 mIU/L could be physiologically euthyroid. We disagree and 
provide 3 specific points in response. 
When we designed the TRUST trial, we chose to set a TSH target of 0.40-4.59 mIU/L with levothyroxine treatment, which 
was the range used to define euthyroidism in the Thyroid Studies Collaboration2 and contemporary guidelines,3 despite the 
current discussion of using an age-specific reference.4 
We enrolled only participants who had persistent elevated TSH levels (4.60-19.99 mIU/L).1,5 The TSH value was required 
to be within the eligibility window on at least 2 occasions that were 3 months to 3 years apart. In the TRUST trial, among the 
2647 older adults screened for eligibility, 1645 did meet inclusion criteria because of a reversion of TSH level.5 The TSH 
levels among participants randomized in the placebo group remained elevated over the study period (5.29 mIU/L in average).1 
Therefore, we can assume that participants who were truly euthyroid were not studied in the TRUST trial. 
The proportion of older participants with TSH ≥7 mIU/L in our study (23.8%) was representative, as the prevalence of such 
abnormality at this age category accounts for about 10% of the elderly population.4 In our study, prespecified stratification 
according to baseline TSH levels (4.6-6.9, 7.0- 9.9, ≥10 mIU/L) yielded similar results without statistical interactions.1 These 
findings were replicated in another trial of patients with subclinical hypothyroidism where levothyroxine compared with 
placebo had no impact on cardiac function.6 Because the vast majority of patients treated for subclinical hypothyroidism in 
practice have a TSH value between 4.6 and 6.9 mIU/L,4 the inclusion of those participants enabled us to evaluate the 
treatment effect of levothyroxine in this key subgroup. 
Although we agree that age-specific reference for the diagnosis of subclinical hypothyroidism in the elderly needs to be re-
discussed,4 current findings found no benefits of levothyroxine on cardiac function among older adults with subclinical 
hypothyroidism, including among those with TSH ≥7 mIU/L.1,6 
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